Q-omics provides the consensus-scored TACSTD2 profile across patient tissues and cancer cell-line models. TACSTD2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TACSTD2 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, TACSTD2 RNA expression shows 15,849 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, KIRC, and THYM as cancer lineages where TACSTD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TACSTD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TACSTD2 survival associations across molecular data types. TACSTD2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TACSTD2 RNA expression–survival associations across cancer types. High TACSTD2 expression shows unfavorable associations in OV, LGG, SCLC and ACC, but favorable associations in KICH and LUSC. The KICH Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify KICH as the clearest survival context for TACSTD2 RNA expression.
This table summarizes TACSTD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TACSTD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TACSTD2 shows lower tumor expression in KIRC, KICH, KIRP and LIHC and higher tumor expression in THCA and COAD. The KIRC box plot shows higher TACSTD2 RNA expression in normal versus tumor tissue (log2 FC = −5.300, t-test p < 0.001).
This table shows molecular features associated with TACSTD2 in patient tissues and cancer cell lines. In patient samples, TACSTD2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TACSTD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
